1. Genome–Epigenome–Senescence: Is TET1 a Caretaker of p53-Injured Lung Cancer Cells ?
- Author
-
Yutaka Kondo
- Subjects
0301 basic medicine ,Senescence ,Cancer Research ,Lung Neoplasms ,Mutant ,Chromosomal translocation ,Biology ,Article ,Mixed Function Oxygenases ,03 medical and health sciences ,0302 clinical medicine ,Proto-Oncogene Proteins ,medicine ,Humans ,Doxorubicin ,Transversion ,Lung cancer ,Cellular Senescence ,Cisplatin ,Epigenome ,medicine.disease ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Cancer research ,Tumor Suppressor Protein p53 ,medicine.drug - Abstract
The study by Filipczak and colleagues identified the interplay between mutant p53 proteins and methylcytosine dioxygenase ten-eleven translocation 1 (TET1) in lung cancers. p53 transversion mutations were closely associated with high TET1 expression, which prevented genomic instability–associated cellular senescence. Depletion of TET1 was synergistic with classical antitumor drugs, such as cisplatin or doxorubicin, providing an attractive rationale for targeted therapies against TET1 combined with antitumor drugs in patients with p53-mutant lung cancer., ファイル公開:2020/04/01
- Published
- 2019